
Stanford-based AIRNA pioneers RNA editing therapies for rare and common health ailments.
Founded in Stanford, California, AIRNA is a biotech company dedicated to transforming the lives of patients through innovative RNA editing therapies. Their core mission is to develop groundbreaking treatments for both rare and common diseases, leveraging advanced RNA editing techniques. AIRNA's vision is to revolutionize healthcare by providing precise, effective, and personalized therapeutic solutions. Their market focus includes addressing unmet medical needs and improving patient outcomes across a broad spectrum of health conditions.
Notable affiliated individuals include leading scientists and researchers from prestigious institutions, contributing to AIRNA's cutting-edge advancements. The company has attracted significant investment from top-tier venture capital firms, underscoring confidence in its potential. Key achievements include successful preclinical trials and partnerships with major pharmaceutical companies. Overall, AIRNA's impact lies in its potential to offer life-changing treatments, setting new standards in the biotech industry and offering hope to millions of patients worldwide.
Rnav8 Bio

Locanabio

Amber Bio
amber.bio

Rnaimmune
rnaimmune.com

Alltrna
alltrna.com

ReviR Therapeutics
revirtx.com

Laronde
laronde.bio

Orbital Therapeutics

Inceptive
inceptive.life

Nextrna Therapeutics

ReNAgade Therapeutics

Wayfinder Biosciences
wayfinderbio.com

Rnaderm Therapeutics

Korro Bio
korrobio.com

Enzerna
enzerna.com
Companies similar to Airna include Rnav8 Bio, Locanabio, Amber Bio and Rnaimmune.
Airna was founded in 2021.
Airna's headquarters is located in Stanford, CA, US.
Airna's most recent funding round was for $30M (USD) in September 2023.
As of Sep 19, 2023, Airna has raised a total of $30M (USD).
Airna has 30 employees as of Feb 5, 2024.